
Paige Stock
A Global Leader in Digital Diagnostics
Sign up today and learn more about Paige Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Paige Stock
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
Funding History
February 2018 | $25.0M |
---|---|
December 2019 | $45.0M |
April 2020 | $5.0M |
July 2020 | $20.0M |
January 2021 | $125M |
Management
Founder & Chief Scientific Officer
Thomas Fuchs
CEO
Leo Grady
Chief Business Development Officer
Carla Leibowitz
VP Engineering
Razik Yousfi
Board Member
David Castelblanco
Co-Founder & Senior Machine Learning Scientist
Peter Schüffler
Investor and Board Member
Jim Breyer
Member Board Of Directors
Asish Xavier
VP Engineering
Razik Yousfi
Press
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase